Education
About Us
Working with TipRanks
Follow Us
23Andme Holding Co (MEHCQ)
:MEHCQ
23Me-01473
Solid Tumor
Phase I/II
Terminated
Study of 23ME-01473 in Patients With Advanced Solid Malignancies
Feb 08, 2024
―
23Me-00610
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Solid Tumor, Neuroendocrine Tumors, Clear Cell Renal Cell Carcinoma, Extensive-Stage Small-Cell Lung Cancer, Msi-H Cancer, Cancer With A High Tumor Mutational Burden
Phase I/II
Active Not Recruiting
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Jan 06, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does 23Andme Holding Co (MEHCQ) have in its pipeline
MEHCQ is currently developing the following drugs: 23Me-01473, 23Me-00610. These drug candidates are in various stages of clinical development as the company works toward FDA approval.